Association of laboratory test results with the bleeding history in patients with inherited platelet function disorders (the Bleeding Assesment Tool - LABoratory tests substudy): communication from the Platelet Physiology ISTH-SSC.

ISTH-BAT bleeding score blood platelets hemorrhage inherited platelet function disorders platelet function tests

Journal

Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 09 03 2023
revised: 20 11 2023
accepted: 04 12 2023
medline: 31 1 2024
pubmed: 31 1 2024
entrez: 31 1 2024
Statut: epublish

Résumé

In hemophilia and von Willebrand disease, the degree of alteration of laboratory assays correlates with bleeding manifestations. Few studies have assessed the predictive value for bleeding of laboratory assays in patients with inherited platelet function disorders (IPFDs). To assess whether there is an association between platelet function assay results and bleeding history, as evaluated by the International Society on Thrombosis and Haemostasis (ISTH) bleeding assessment tool (BAT). Centers participating in the international ISTH-BAT validation study were asked to provide results of the diagnostic assays employed for the patients they enrolled, and the association with the individual patients' bleeding score (BS) was assessed. Sixty-eight patients with 14 different IPFDs were included. Maximal amplitude of platelet aggregation was significantly lower in patients with a pathologic BS and correlated inversely with the BS, a finding largely driven by the subgroup of patients with Glanzmann thrombasthenia and CalDAG-GEFI deficiency; after their exclusion, TRAP-induced aggregation remained significantly lower in patients with a pathologic BS. Bleeding time was significantly more prolonged in patients with a high BS than in those with a normal BS (27.1 ± 6.2 minutes vs 15.1 ± 10.6 minutes; This study shows that altered platelet laboratory assay results are associated with an abnormal ISTH-BAT BS in IPFD.

Sections du résumé

Background UNASSIGNED
In hemophilia and von Willebrand disease, the degree of alteration of laboratory assays correlates with bleeding manifestations. Few studies have assessed the predictive value for bleeding of laboratory assays in patients with inherited platelet function disorders (IPFDs).
Objectives UNASSIGNED
To assess whether there is an association between platelet function assay results and bleeding history, as evaluated by the International Society on Thrombosis and Haemostasis (ISTH) bleeding assessment tool (BAT).
Methods UNASSIGNED
Centers participating in the international ISTH-BAT validation study were asked to provide results of the diagnostic assays employed for the patients they enrolled, and the association with the individual patients' bleeding score (BS) was assessed.
Results UNASSIGNED
Sixty-eight patients with 14 different IPFDs were included. Maximal amplitude of platelet aggregation was significantly lower in patients with a pathologic BS and correlated inversely with the BS, a finding largely driven by the subgroup of patients with Glanzmann thrombasthenia and CalDAG-GEFI deficiency; after their exclusion, TRAP-induced aggregation remained significantly lower in patients with a pathologic BS. Bleeding time was significantly more prolonged in patients with a high BS than in those with a normal BS (27.1 ± 6.2 minutes vs 15.1 ± 10.6 minutes;
Conclusion UNASSIGNED
This study shows that altered platelet laboratory assay results are associated with an abnormal ISTH-BAT BS in IPFD.

Identifiants

pubmed: 38292347
doi: 10.1016/j.rpth.2023.102305
pii: S2475-0379(23)05733-3
pmc: PMC10825541
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102305

Informations de copyright

© 2023 The Author(s).

Auteurs

Paolo Gresele (P)

Section of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.

Emanuela Falcinelli (E)

Section of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.

Loredana Bury (L)

Section of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.

Marie-Christine Alessi (MC)

Centre for CardioVascular and Nutrition Research, Institut National de la Sante et de la Recherche Medicale 1263, Institut National de la Recherche Agronomique 1260, Marseille, France.

Giuseppe Guglielmini (G)

Section of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.

Céline Falaise (C)

Centre for CardioVascular and Nutrition Research, Institut National de la Sante et de la Recherche Medicale 1263, Institut National de la Recherche Agronomique 1260, Marseille, France.

Gianmarco Podda (G)

Dipartimento di Scienze della Salute, Medicina III, Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo, Università degli Studi di Milano, Milano, Italy.

Mathieu Fiore (M)

Laboratory of Hematology, University Hospital of Bordeaux, Pessac, France.

Francesco Mazziotta (F)

Section of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.

Teresa Sevivas (T)

Serviço de Sangue e Medicina Transfusional, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.

Nuria Bermejo (N)

Hospital San Pedro de Alcantara, Caceres, Spain.

Erica De Candia (E)

Hemostasis and Thrombosis Unit, Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Roma, Italy.
Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Roma, Italy.

Meera Chitlur (M)

Children's Hospital of Michigan, Detroit, Michigan, USA.

Michele P Lambert (MP)

Children's Hospital of Philadelphia, Philadelphia, USA.

Luca Barcella (L)

Immunohematology and Transfusion Medicine & Hemostasis and Thrombosis Center, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.

Ana C Glembotsky (AC)

Instituto de Investigaciones Médicas A. Lanari, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
Departamento Hematología Investigación, Consejo Nacional de Investigaciones Científicas y Tecnológicas, Universidad de Buenos Aires, Instituto de Investigaciones Médicas, Buenos Aires, Argentina.

Marie Lordkipanidzé (M)

Université de Montréal, Montréal, Québec, Canada.
Research Center, Montreal Heart Institute, Montréal, Québec, Canada.

Classifications MeSH